key: cord-0316146-a6rz2l2q
authors: Aguinagalde, Leire; den Boer, Maurits A.; Castenmiller, Suzanne M.; Zwarthoff, Seline A.; Gosselaar-de Haas, Carla J.C; Aerts, Piet C.; Beurskens, Frank J.; Schuurman, Janine; Heck, Albert J.R.; van Kessel, Kok P.M.; Rooijakkers, Suzan H.M.
title: Promoting Fc-Fc interactions between anti-capsular antibodies provides strong complement-dependent immune protection against Streptococcus pneumoniae
date: 2022-01-21
journal: bioRxiv
DOI: 10.1101/2022.01.21.477211
sha: 027613b32c435a4a74771830c9739dc660bb9981
doc_id: 316146
cord_uid: a6rz2l2q

Streptococcus pneumoniae is the leading cause of community-acquired pneumonia and an important cause of childhood mortality. Despite the introduction of successful vaccines, the global spread of both non-vaccine serotypes and antibiotic-resistant strains reinforce the development of alternative therapies against this pathogen. One possible route is the development of monoclonal antibodies (mAbs) that induce killing of bacteria via the immune system. Here we investigate whether mAbs can be used to induce killing of pneumococcal serotypes for which the current vaccines show unsuccessful protection. Our study demonstrates that when human mAbs against pneumococcal capsule polysaccharides (CPS) have a poor capacity to induce complement activation, a critical process for immune protection against pneumococci, their activity can be strongly improved by hexamerization-enhancing mutations. Our data indicate that anti-capsular antibodies may have a low capacity to form higher-order oligomers (IgG hexamers) that are needed to recruit complement component C1. Indeed, specific point mutations in the IgG-Fc domain that strengthen hexamerization strongly enhance C1 recruitment and downstream complement activation on encapsulated pneumococci. Specifically, hexamerization-enhancing mutations E430G or E345K in CPS6-IgG strongly potentiate complement activation on S. pneumoniae strains that express capsular serotype 6 (CPS6), and the highly invasive serotype 19A strain. Furthermore, these mutations improve complement activation via mAbs recognizing CPS3 and CPS8 strains. Importantly, hexamer-enhancing mutations enable mAbs to induce strong phagocytosis and intracellular killing by human neutrophils. Finally, passive immunization with CPS6-IgG1-E345K protected mice from developing severe pneumonia. Altogether, this work provides insights that are crucial for optimizing antibody therapies against encapsulated S. pneumoniae.

frequently found to be causing invasive pneumococcal disease (IPD). Besides the fact that the 56 widespread vaccination has been highly effective in lowering IPD caused by vaccine serotypes (9-57 11), there still is a large burden of pneumococcal disease caused by non-vaccine serotypes. 58 Furthermore, because some vaccine serotypes induce a weak immune response it remains difficult 59 to control pneumococcal disease, particularly in risk groups (12). Finally, the emergence of strains 60 with high level of antibiotic resistance (13-16) highlight a strong need to develop new therapeutic 61 strategies against pneumococcal infections.

In recent years, antibody therapies have emerged as a successful treatment for several autoimmune 63 diseases and cancers (17, 18) . Therefore, there is now also great interest in development of 64 antibody-based therapies against bacterial infections. To eliminate bacteria, antibodies should bind

Hexamer-enhancing mutations enable anti-capsular antibodies to activate complement on S. 96 pneumoniae serotype 6B 97 To study whether human mAbs can induce complement activation on encapsulated S. pneumoniae 98 strains, we first investigated complement activation on S. pneumoniae 6B, a common serotype 99 infecting both adults and children (32, 33) . Although serotype 6B is covered by current vaccines, 100 the 6B capsule type is found to be poorly immunogenic and an important risk factor in the mortality 101 by IPD (32-34). We generated recombinant variants of a previously identified human IgG1 After verifying that the introduction of hexamer-enhancing mutations did not affect the binding of 112 CPS6-IgG1 antibodies to serotype 6B (Figure 1c and S2), we studied their capacity to induce 113 complement activation. To this end, 6B pneumococcus was incubated with mAbs in the presence 114 of human serum as complement source. To exclude the involvement of pre-existing antibodies, we 115 used human serum that was depleted from naturally occurring IgG and IgM (36) (denoted 116 IgG/IgM-depleted serum). Using surface-specific staining of C1q and flow cytometry, we first 117 determined the capacity of mAbs to recruit C1q ( Figure S1 ). While the wild-type (WT) IgG1 showed little to no reactivity with C1q, we noted that the introduction of hexamer-enhancing 119 mutations E430G or E345K strongly enhanced the ability to interact with C1q (Figure 1d) . 120 Importantly, we found that introduction of hexamer-enhancing mutations in CPS6-IgG1 allowed 121 activation of the classical complement pathway. Recruitment of C1q to target-bound IgGs induces 122 activation of C1q-attached C1r and C1s proteases that cleave C4 to covalently attach activated C4b 123 molecules onto the bacterial surface ( Figure S1 ) (37). Furthermore, C1 activates C2 to produce a 124 6 C3 convertase (C4b2b) that deposits large amounts of C3b, a key component of the complement 125 cascade that labels bacteria for phagocytosis (38, 39) . Indeed, by monitoring deposition of C4b and 126 C3b molecules, we observed that Fc-engineered variants of CPS6-IgG1, but not the WT antibody, 127 potently induced deposition of C4b (Figure 1e ) and C3b molecules (Figure 1f ) onto serotype 6B.

Altogether, these data show that hexamer-enhancing mutations can overcome poor complement 129 activation by monoclonal antibodies against capsular serotype 6. 

For both E430G and E345K mutated variants, we found that 0.3 μg/ml of mAb induced maximum 146 phagocytosis in the presence of 2.5% IgG/M-depleted serum (Figure 2a) . When serum was heat-147 treated to inactivate complement (45), we found that phagocytosis by E430G and E345K 148 antibodies was completely abolished (Figure 2b) . Bacterial internalization in presence of active 149 complement and antibodies was confirmed by microscopy (Figure 2c) (Figure 2d and S4) . The fact that we observed binding of Fc-III to 163 monomeric IgG1, but not to larger oligomeric species, suggests that Fc-III inhibits IgG-mediated 164 complement activation by competitive binding to the Fc-Fc interaction interface of IgG monomers.

In line with our hypothesis, we found that Fc-III potently blocked phagocytic uptake of serotype 166 6B via both E430G and E345K mutants, while Scr showed no effect (Figure 2e) . 167 Taken together, while a WT monoclonal antibody against CPS6 has a poor capacity to induce 168 phagocytosis of S. pneumoniae serotype 6B, introduction of hexamerization-enhancing mutations 169 strongly increases complement-mediated phagocytosis. IgG2 (49-51), we also constructed human monoclonal CPS6-IgG2. While WT and Fc-Fc 175 enhancing variants showed equal binding to serotype 6B (Figure S5a) , we again observed that 176 hexamer-enhancing mutations E430G and E345K both improved C3b deposition in IgG2 ( Figure   177 3a).Also for IgG3 antibodies, which are considered more effective in the induction of Fc-effector 178 functions (52), we found that hexamer-enhancing mutation E345K significantly increased C3b 179 deposition, while a much less strong enhancement was observed for E430G (Figure 3b) . A direct 180 comparison of E345K variants shows that CPS6-IgG1-E345K activated complement more 181 8 potently than CPS6-IgG3-E345K and CPS6-IgG2-E345K ( Figure S5e) , even though the binding 182 is the same (Figure S5c ). 183 Consistent with the results for C3b deposition, we observed that E345K, but not E430G, enhanced (Figure 6c, S9a) . In contrast, 100 μg CPS6-IgG1-E345K could rescue 50% of 260 mice (10/20). Again, we observed that the CPS6-IgG1-E345K mAb was more potent in protecting 261 mice than CPS6-IgG1-WT. Additionally, mice weight regain was very much associated with the 262 protective capacity of each mAb ( Figure S9b) . 263 When repeating the same experiments in male BALB/c mice, we observed that 100 μg CPS6-264 IgG1-E345K and 300 μg CPS6-IgG1-E345K could not confer significant protection against 265 bacteremia ( Figure S10 ). However, these mAbs were able to control bacterial spread from lungs 266 to the bloodstream within 24h after infection in the same proportion as in female mice ( Figure   267 S10b. Although this needs further investigation, these data potentially indicate gender differences 268 in immune protection to pneumococcal infections.

Altogether, these data suggest that passive immunization with complement-enhancing monoclonal 270 antibodies can prevent mice from developing bacteremia by encapsulated pneumococci. Overall, these results confirmed that antibodies directed against CPS could be used as therapy 286 target as they can be modified to enhance hexamer formations, having strong positive influence 287 on complement deposition and phagocytosis of highly virulent S. pneumoniae strains. Pneumococcal infection in mice 500 The pneumococcal infection model has been described before (88,94). In brief, mice were 501 passively immunized intraperitonealy (i.p.) with 200 μl of antibody in PBS, 3h before challenge.

Mice were anesthetized with inhaled isoflurane at 3% and challenged by intranasal (i.n.) route with 503 1 × 10 8 CFU pneumococci serotype 6A in 50 μl PBS. Every twenty-four hours after challenge 504 animals were weighted, scored by 2 independent researchers and blood was taken from tail vein.

When mice exhibited severe signs of disease they were sacrificed according to the national 506 guidelines. Blood was serially diluted, and plated on Colombia agar containing 5% sheep blood 507 (Sanofi Diagnostics Pasteur, Marnes-la-coquette, France). Plates were incubated overnight at 508 37°C, and pneumococcal colonies were counted. Animals that survived for 7 day were considered 509 protected. Dashed line represents background (no IgG) level. Two-way ANOVA was used to compare across dose-response curves at the various concentrations the differences between the WT and the E430G or E345K variants. When significant it was displayed as *P < 0.05; ***P < 0.001; ****P < 0.0001. (a, b) Phagocytosis by human neutrophils of fluorescence labelled S. pneumoniae serotype 3 (a) and serotype 8 (b) after incubation with 5% human normal sera supplemented with CPS-IgG1-WT, CPS-IgG1-E430G or CPS-IgG1-E345K variant. All data represent relative fluorescence mean index ± SD of three independent experiments compared to the highest CPS-IgG1-WT concentration tested (8 µg/ml). Dashed line represents background (no IgG) level. Two-way ANOVA was used to compare across dose-response curves at the various concentrations the differences between the WT and the E430G or E345K variants. When significant it was displayed as *P < 0.05; ***P < 0.001; ****P < 0.0001.

Localization of Complement Component 3

The interrelationship between phagocytosis, autophagy 638 and formation of neutrophil extracellular traps following infection of human neutrophils 639 by Streptococcus pneumoniae

Neutrophil evasion strategies by Streptococcus pneumoniae 641 and Staphylococcus aureus

Fcγ receptors: Old friends and new family members

Macrophage complement receptors 645 and pathogen clearance. Cellular Microbiology

Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated 648 neutrophil rolling

Contribution of the 650 complement Membrane Attack Complex to the bactericidal activity of human serum

Convergent solutions to binding at a 653 protein-protein interface. Science (80-)

Native Mass Spectrometry: What is in the Name?

High-Resolution Native Mass Spectrometry

Serum IgG-2 Concentrations and the Antibody Response to Bacterial Polysaccharide 660

IgG subclass distribution of antibodies to bacterial and viral 662 antigens

IgG subclasses and allotypes: from structure to 666 effector functions. Front Immunol

Serotype 19A is 670 the most common serotype causing invasive pneumococcal infections in children

Streptococcus 673 pneumoniae serotype 19A: worldwide epidemiology

Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 677 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands

Pneumococcal 680 serotypes before and after introduction of conjugate vaccines

Changing 683 Epidemiology of Antimicrobial-Resistant Streptococcus pneumoniae in the United States

Shifting 686 genetic structure of invasive serotype 19A pneumococci in the United States

Emergence of a 689 multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain

Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A 693 among children in Barcelona

Serotypic variations among virulent pneumococci in deposition and 695 degradation of covalently bound C3b: Implications for phagocytosis and antibody 696 production

Natural antibodies against several pneumococcal virulence proteins in children during the 699 pre-pneumococcal-vaccine era: The generation R study

Natural development of antibodies against Streptococcus pneumoniae, Haemophilus 702 influenzae, and Moraxella catarrhalis protein antigens during the first 13 years of life

Streptococcus pneumoniae: Transmission, 705 colonization and invasion

Pneumococcal pneumonia and bacteremia model in 707 mice for the analysis of protective antibodies

Efficacy of opsonic and 709 nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal 710 antibodies against intranasal challenge with streptococcus pneumoniae in mice ∇. Infect 711 Immun

Characterization of Gene Use and Efficacy of Mouse Monoclonal 713

Antibodies to Streptococcus pneumoniae Serotype 8

Serotype-specific 716 mortality from invasive Streptococcus pneumoniae disease revisited

Population 719 structure and drug resistance patterns of emerging non-PCV-13 Streptococcus 720 pneumoniae serotypes 22F, 15A

Invasive pneumococcal disease: Association between serotype, clinical presentation 724 and lethality

Antibodies to watch in 2021

The monoclonal 727 antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in 728 preclinical and human studies

Tackling COVID-19 with neutralizing 730 monoclonal antibodies

A New Take on an Old Remedy: Generating Antibodies against 732

Multidrug-Resistant Gram-Negative Bacteria in a Postantibiotic World

C1q binding 735 to surface-bound IgG is stabilized by C1r2s2 proteases

Host Interaction

Structure-function relationships for 739 human antibodies to pneumococcal capsular polysaccharide from transgenic mice with 740 human immunoglobulin loci

Let's tie the knot: Marriage of complement 742 and adaptive immunity in pathogen evasion, for better or worse. Frontiers in 743 Microbiology

Homozygosity for the IgG2 Subclass Allotype G2M(n) Protects against Severe Infection 746 in Hereditary C2 Deficiency

Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody

Bacteria under 752 stress by complement and coagulation

Antimicrobial susceptibility and 754 fluctuations in clonal complexes of serogroup 6 Streptococcus pneumoniae isolates 755 collected from children in Beijing

Epidemiology of Streptococcus pneumoniae Serogroup 6 Isolates from IPD in Children 759 and Adults in Germany

Denmark14-761 230 clone as an increasing cause of pneumococcal infection in Portugal within a 762 background of diverse serotype 19A lineages

Isolation and Characterization of Human Monoclonal 764

Complement-Mediated Activation of the Adaptive Immune 766 Responses

Staphylococcal protein A inhibits complement activation by interfering with IgG hexamer 769 formation

Central Role of Complement in Passive Protection by Human IgG1 and IgG2 Anti-772 pneumococcal Antibodies in Mice

Humanized monoclonal 774 antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide 775 sequence of cDNA constructs and comparison of effector mechanisms of myeloma

Chinese hamster ovary cell-derived material

Impaired opsonization 778 with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with 779 defects in the classical complement pathway

Use of Flow Cytometry to Evaluate Phagocytosis of Staphylococcus aureus by Human 782 Neutrophils

Immune 784 evasion by a staphylococcal inhibitor of myeloperoxidase

Bayesian deconvolution of mass and ion mobility spectra: From binary interactions to 788 polydisperse ensembles

Pneumococcal pneumonia and bacteremia model in 790 mice for the analysis of protective antibodies

Figure 2. Hexamerization-enhanced variants of CPS6-IgG1 trigger complement-dependent phagocytosis of serotype 6B S. pneumoniae

Fluorescently labelled bacteria uptake by human neutrophils in the presence of 2.5% IgG/IgM-depleted serum supplemented with CPS6-IgG1-WT versus E430G and E345K variants. (b) Comparison of S. pneumoniae serotype 6B phagocytosis by CPS6-IgG1-WT, E430G or E345K antibody variants at 4 µg

Diff-Quik) and pictures taken using a 100X objective to visualize cytoplasmic internalization. (d) Native mass spectra of IgG1-RGY in the absence (black) and presence of Fc-Fc inhibitor peptide Fc-III (red) or a scrambled version Scr (blue). Spectra are shifted for clarity and monomeric (IgG1)1 and hexameric (IgG1)6 mass peaks are indicated. Inset represents the percentage (IgG1)6 for each sample. (e) Phagocytosis of fluorescently labelled S. pneumoniae 6B after incubation with 2.5% IgG/M-depleted serum supplemented with CPS6-IgG1-WT, CPS6-IgG1-E430G or CPS6-IgG1-E345K, in presence or absence of 10 μg/ml Fc-Fc inhibitory peptide (Fc-III) and a scrambled version (Scr). (a, b, e) Bacterial uptake is displayed as the mean fluorescence value of neutrophils relative to CPS6-IgG1-WT at the highest concentration tested (8 μg/ml). Data represent mean ± SD of three independent experiment. (a) Dashed line represents background (buffer) level

**** **** **** **** **** **** **** **** * Figure 2